ES2189059T3 - Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion. - Google Patents

Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.

Info

Publication number
ES2189059T3
ES2189059T3 ES98117718T ES98117718T ES2189059T3 ES 2189059 T3 ES2189059 T3 ES 2189059T3 ES 98117718 T ES98117718 T ES 98117718T ES 98117718 T ES98117718 T ES 98117718T ES 2189059 T3 ES2189059 T3 ES 2189059T3
Authority
ES
Spain
Prior art keywords
talidomide
procedure
preparation
parenteral administration
new prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98117718T
Other languages
English (en)
Inventor
Sven Bjorkman
Peter Hoglund
Tommy Eriksson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7844650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2189059(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2189059T3 publication Critical patent/ES2189059T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA SOLUCION ACUOSA DE TALIDOMIDA, QUE ES APROPIADA PARA SU INYECCION PARENTERAL, EN PARTICULAR INTRAVENOSA DE LA TALIDOMIDA PARA LA TERAPIA DE ENFERMEDADES INMUNOLOGICAS, ASI COMO UN PROCEDIMIENTO PARA LA PREPARACION DE LA CORRESPONDIENTE SOLUCION DE TALIDOMIDA.
ES98117718T 1997-10-06 1998-09-18 Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion. Expired - Lifetime ES2189059T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19743968A DE19743968C2 (de) 1997-10-06 1997-10-06 Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Publications (1)

Publication Number Publication Date
ES2189059T3 true ES2189059T3 (es) 2003-07-01

Family

ID=7844650

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98117718T Expired - Lifetime ES2189059T3 (es) 1997-10-06 1998-09-18 Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.

Country Status (14)

Country Link
US (1) US6124322A (es)
EP (1) EP0908176B1 (es)
JP (1) JPH11189534A (es)
AT (1) ATE229323T1 (es)
AU (1) AU732634B2 (es)
CA (1) CA2248838A1 (es)
DE (2) DE19743968C2 (es)
DK (1) DK0908176T3 (es)
ES (1) ES2189059T3 (es)
HK (1) HK1018591A1 (es)
HU (1) HUP9802206A1 (es)
NZ (1) NZ331563A (es)
PT (1) PT908176E (es)
SI (1) SI0908176T1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
ATE235256T1 (de) * 1999-03-31 2003-04-15 Gruenenthal Gmbh Stabile wässrige lösung von 3-(1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin-2,6-dion
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
AU5448300A (en) * 1999-05-27 2000-12-18 Rockefeller University, The Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
GB2371767A (en) * 2001-02-02 2002-08-07 Labman Automation Ltd Dissolving materials by application of agitation and ultrasound
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
CN1867331B (zh) 2003-09-17 2010-05-26 美国政府健康及人类服务部 作为TNF-α调节剂的沙利度胺类似物
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
AU2020263285A1 (en) * 2019-04-22 2021-10-28 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
DE4211812C2 (de) * 1991-04-17 1994-05-05 Gruenenthal Gmbh Thalidomidderivate, ein Verfahren zu deren Herstellung sowie die Verwendung derselben in Arzneimitteln
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
EP0908176A1 (de) 1999-04-14
CA2248838A1 (en) 1999-04-06
NZ331563A (en) 1999-01-28
ATE229323T1 (de) 2002-12-15
JPH11189534A (ja) 1999-07-13
HUP9802206A1 (hu) 2000-12-28
HU9802206D0 (en) 1998-11-30
SI0908176T1 (en) 2003-04-30
AU8792598A (en) 1999-04-22
HK1018591A1 (en) 1999-12-30
DE19743968A1 (de) 1999-04-15
AU732634B2 (en) 2001-04-26
EP0908176B1 (de) 2002-12-11
DE19743968C2 (de) 2002-07-11
PT908176E (pt) 2003-04-30
DE59806612D1 (de) 2003-01-23
DK0908176T3 (da) 2003-01-06
US6124322A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
ES2189059T3 (es) Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
EA199800946A1 (ru) Концентрированный препарат антител
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
MY124695A (en) Novel composition and use.
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
AR025428A1 (es) Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asicomo eventualmente otros excipientes
ES2033871T3 (es) Un procedimiento para producir una preparacion de insulina para administracion parenteral.
SI1285667T1 (sl) Farmacevtske raztopine za injiciranje paracetamola ali kombinacij paracetamola z drugimi aktivnimi substancami
DE60125417D1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
DE69928815D1 (de) Dosierungsform mit flüssiger formulierung
ES2193216T3 (es) Dipeptidil peptidasa iv y su procedimiento de preparacion.
DK1007055T3 (da) Anvendelse af amifostin
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
RS52011B (sr) Nova primena derivata taksoida
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
ES2174297T3 (es) Nuevos derivados de piranosidos.
ES2194994T3 (es) Procedimiento para la obtencion de caprolactama.
ES2177769T3 (es) Derivado de aminotetralina para la terapia de trastornos cardiovascu lares.
AR023199A1 (es) Solucion acuosa estable de em12, y procedimiento de preparacion de dicha solucion
ATE305796T1 (de) Präparationen von vitamin e in kombination mit afamin